Viking Therapeutics, Inc. VKTX

Underwriters exercised their options in full, lifting the financing above Viking’s initial $400 million proposal.

Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its concurrent upsized public offerings of 9,035,714 shares of common stock, at a public offering price of $35.00 per share, and $258.75 million aggregate principal amount of 2.00% convertible senior notes due 2032 (the "notes"), which included the full exercise by the underwriters of the common st

A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.

Viking Therapeutics has ridden a powerful share price run and a wave of enthusiasm around its weight loss pipeline. This now puts a spotlight on a quieter question. At today’s level, the issue is whether the stock price lines up with the biopharma group’s book value when set against the industry average. Over the past 5 years, Viking Therapeutics has delivered a very large share price gain. This raises the stakes for whether current investors are paying a level that its balance sheet can...

The Nasdaq hit a new high this week, but the Dow Jones set fresh three-month lows as Treasury yields skyrocketed.

Investing.com -- Viking Therapeutics Inc. completed a $500 million capital raise through a two-part offering, with one investor acquiring approximately one-third of the shares in the upsized equity portion, Bloomberg reported Thursday.